Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 5:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 728 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Systemic Inflammatory Response Syndrome (SIRS) Clear all
Completed Phase 2 Interventional Results available

Citrulline in Severe Sepsis

NCT01474863
View directory record Official record
Conditions
Severe Sepsis, Acute Lung Injury
Interventions
High Dose Citrulline, Placebo, Low Dose Citrulline
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
13 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 4, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Comparison of Infection Rates Among Patients Using Two Catheter Access Devices

NCT00965198
View directory record Official record
Conditions
Catheter-Related Infections, Bacteremia
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

ASAP: Access to Syringes at Pharmacies for the Prevention of Bloodborne Infections Among People Who Inject Drugs

NCT05270135
View directory record Official record
Conditions
Skin and Soft Tissue Infections, Hiv, Hepatitis C, Bloodstream Infection
Interventions
ASAP
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 18, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

SHOCK US STUDY: Fluid Responsiveness in Sepsis Measured by Ultrasonography

NCT02170233
View directory record Official record
Conditions
Sepsis
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational

CLEAR Sepsis Clinical Study

NCT03231956
View directory record Official record
Conditions
Sepsis
Interventions
ClearSight™ / EV1000NI Clinical Platform
Device
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Detroit, Michigan • Royal Oak, Michigan • Troy, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects

NCT02439359
View directory record Official record
Conditions
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Interventions
CF-301, Placebo
Drug
Lead sponsor
ContraFect
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
Lenexa, Kansas • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 6, 2020 · Synced Sep 17, 2026, 5:15 AM EDT
Not yet recruiting Phase 2 Interventional

Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp

NCT07803562
View directory record Official record
Conditions
Uveal Melanoma, Metastatic
Interventions
Dexamethasone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational

POC SPLA2-IIA as a Biomarker for Sepsis and Septic Shock

NCT03953404
View directory record Official record
Conditions
Sepsis
Interventions
SPLA2-IIA
Diagnostic Test
Lead sponsor
St. Luke's Hospital, Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
450 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethlehem, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 16, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

The AVERT Sepsis Investigation

NCT01968746
View directory record Official record
Conditions
Sepsis, Severe Sepsis
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Denver, Colorado • Newark, Delaware • Billings, Montana + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Sep 17, 2026, 5:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Assessing Immune Dysfunction in Sepsis

NCT07154615
View directory record Official record
Conditions
Sepsis
Interventions
Observational Only
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis

NCT00042588
View directory record Official record
Conditions
Pneumonia, Sepsis
Interventions
Recombinant Chimeric Monoclonal Antibody
Drug
Lead sponsor
ICOS Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Bothell, Washington
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Genetic Variation and Immune Responses After Injury

NCT00294697
View directory record Official record
Conditions
Sepsis, Pneumonia, Trauma, Burn, Injury
Interventions
Not listed
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Performance Evaluation of the Nanomix eLab® CRP, PCT, and LAC Assays With the Nanomix eLab System

NCT03876535
View directory record Official record
Conditions
Sepsis, SIRS
Interventions
Nanomix eLab® System molecular diagnostic test (non-interventional)
Other
Lead sponsor
Nanomix
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis

NCT02244606
View directory record Official record
Conditions
Mycoses, Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Micafungin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2021 · Synced Sep 17, 2026, 5:15 AM EDT
Completed No phase listed Observational

Sepsis Post Market Clinical Utility Simple Endpoint Study - Indiana University Hospital

NCT04819035
View directory record Official record
Conditions
Sepsis, Adult Disease, Severe Sepsis, Emergency Department
Interventions
CBC-DIFF Monocyte Volume Width Distribution (MDW)
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
18 Years to 89 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

NCT01000649
View directory record Official record
Conditions
Septic Shock
Interventions
FE 202158 1.25, FE 202158 2.5, FE 202158 3.75, Placebo
Drug · Other
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Newark, Delaware • Springfield, Massachusetts • Duluth, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335
View directory record Official record
Conditions
Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2024 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Yellow Fever Virus Vaccine and Immune Globulin Study

NCT00254826
View directory record Official record
Conditions
Viremia
Interventions
YF-VAX® plus saline, 17D YF Vaccine plus Ig,
Biological
Lead sponsor
Emory University
Other
Eligibility
18 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 1 Interventional

Effect of Albumin Administration on Vasopressor Duration in Resolving Septic Shock

NCT02716597
View directory record Official record
Conditions
Shock, Septic
Interventions
25% Albumin, Placebo
Drug
Lead sponsor
Alexander Flannery, 859-323-4011
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Sep 17, 2026, 5:15 AM EDT
Not listed Phase 3 Interventional

Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19

NCT04433949
View directory record Official record
Conditions
Pneumonia, Severe Acute Respiratory Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Low Dose Radiation Therapy
Other · Radiation
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 13, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Phase 2 Interventional

A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

NCT04458298
View directory record Official record
Conditions
COVID-19
Interventions
OP-101, Placebo
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
8
States / cities
Loma Linda, California • Fort Lauderdale, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2023 · Synced Sep 17, 2026, 5:15 AM EDT
Terminated Not applicable Interventional

Safety and Efficacy Study of Ethanol Locking to Prevent Central Line Infection in Premature Neonates

NCT01365312
View directory record Official record
Conditions
Infection Associated With Catheter, Bacteremia, Sepsis
Interventions
Ethanol lock, Heparinized saline
Drug
Lead sponsor
East Carolina University
Other
Eligibility
Up to 32 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2014 · Synced Sep 17, 2026, 5:15 AM EDT
Completed Phase 2 Interventional Results available

HCT+F vs. HCT Alone in Critically Ill Medical Septic Shock Patients

NCT03710187
View directory record Official record
Conditions
Septic Shock
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Tennessee Medical Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Sep 17, 2026, 5:15 AM EDT